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Ann Arbor, MI 48109, U.S.A. 
The development of the aralkylguanidine [13’I]m-iodobenzylguanidine ([i3’I]MIBG) in the University of 
Michigan Nuclear Medicine Division has led to diagnostic and therapeutic evaluations of all the 
neuroendocrine tumors. These tumors share the property of uptake, storage and release of [‘3’I]MIBG 
uptake in chromaffin granules. This property has allowed the detection of pheochromocytomas, the 
detection of metastases in 46% of such patients, the treatment of malignant pheochromocytomas, the 
detection of neuroblastoma metastases. the treatment of neuroblastomas and the detection of a percent 
of apudomas. We have learned how to improve our results and this is discussed. 
Development of 
[‘3’I]m-Iodobenzylguanidine 
the second most promising 
agent (Morales et al., 1976). This lead to a series of 
experiments that attempted to develop 
et al. (1979, 1980) utilizing the lead of Counsel1 
developed the first successful agent for humans, 
[‘3’I]m-iodobenzylguanidine ([‘311]MIBG). This com- 
pound, a structural analog of guanethidine, has cer- 
tain structural similarities to norepinephrine. It was 
shown that the mechanism of uptake of MIBG in 
catecholamine storage granules in sympathetic nerve 
endings and the adrenal medulla is almost identical to 
that of norepinephrine (Wieland et al., 1980). The 
biological half-life of norepinephrine, however, is 
only a few hours in the sympathetic nerve endings 
while that of [“‘I]MIBG in adrenergic tumors is 
several days. 
Pheochromocytomas 
The [13’I]MIBG scan proves that the mass found by 
CAT scanning in a pheochromocytoma because it 
has “specific uptake”. A CAT scan is relatively 
insensitive in detecting extra adrenal pheochromo- 
cytomas in the abdomen or the chest. The [“‘I]MIBG 
scan has excellent sensitivity in localizing pheo- 
chromocytomas in both of these areas. 
In the chest 
Figure 1, a posterior view of [‘3’I]MIBG scinti- 
photo of the chest, shows the sharp localization of a 
pheochromocytoma in the region of the upper part of 
the heart in the mediastinum of a 20 year old woman. 
This woman, in 1977, developed a classical picture 
and laboratory evidence diagnostic of pheochromo- 
cytoma. In 1978, she had extensive invasive and 
traumatic studies in two outstanding Medical 
Centers. These studies included intravenous pye- 
lograms and nephrotomograms, arteriography of the 
abdomen twice, the pelvis once, the chest once, and 
blood sampling from the vena cava on three different 
occasions, CAT scans of the chest and abdomen, 
tomograms of the mediastinum and mastoids, and 
finally a non-productive exploratory laparotomy. 
All of these studies were non-diagnostic and yet 
her plasma norepinephrine was diagnostic at 
16,000 pg/mL (normal < 300 pg/mL). 
After localization by [‘3’I]MIBG scintigraphy, a 
thoracotomy resulted in the successful removal of 
pheochromocytoma, her symptoms disappeared and 
her plasma and urinary catecholamines returned to 
normal. 
In the abdomen 
Figure 2 shows the posterior abdominal 
[‘3’I]MIBG image demonstrating two areas of uptake 
between the kidneys (the 99mTc-DTPA was super- 
imposed on the adrenal scan) of a 30 year old patient. 
This patient illustrates the detection of residual pheo- 
chromocytoma tissues post-operatively when the 
patient has persistent catecholamine excess. The tis- 
sue near the left kidney was only 4mm in diameter 
and was a persistent or recurrent pheochromo- 
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cytoma, while the tissue near the right kidney was 
2cm in diameter. 
Malignant Potential of Pheochromocytoma: 
Implications for Follow-up 
Forty-six percent of 176 patients with pheo- 
chromocytoma studied at the University of Michigan 
over the past 5$ years have had metastases (Beier- 
waltes et al., 1986) compared to the 10% figure 
usually reported (Mangner and Dufford, 1983). 
All 176 patients seen had a review of the original 
histopathology, repeated plasma and urinary cat- 
echolamine measurements, [‘3’I]MIBG scintigraphy 
and comparison with other imaging and localizing 
modalities. For the first 400 patients imaged for 
pheochromocytomas with [‘3’I]MIBG, the sensitivity 
of [“‘I]MIBG imaging for malignant pheochromo- 
cytomas reached 92.4% and the specificity was 100% 
(Shapiro et al., 1985). The criteria for the diagnosis 
of the malignant pheochromocytoma were the 
presence of metastases in the liver, bone, lymph nodes 
and/or lungs. 
A review of the 176 patients with pheochromo- 
cytomas reached 92.4% and the specificity 100% 
(Shapiro et al., 1985). The criteria for the diagnosis 
The other half of the patients have had metastases 
detected. Roughly half of these (n = 38) had their 
metastases detected at the time of the primary oper- 
ation. The other half (n = 43) had their metastases 
detected later. Reviews of the histopathology of 
these three groups showed no statistically significant 
difference histopathologically. 
Figure 3 shows the cumulative incidence of de- 
tection of metastases (n = 81) in percent of patients 
with malignant pheochromocytomas on the ordinate 
and time in years after histopathological diagnosis of 
pheocnromocytoma on the abscissa. It is of interest 
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that the cumulative incidence after the primary 
surgery was 5% per year for the first 9 y and then 
0.6% per year from 9-29 y after the primary surgery. 
This graph indicates that there is an increasing inci- 
dence of demonstrable metastases with the passage of 
time following surgical removal of the “benign” 
pheochromocytoma. This observation is accentuated 
by the additional data that our median follow-up 
after the first histopathologic proof of a pheochromo- 
cytoma was only 2.5 y. In addition, the median period 
between the primary surgery and the detection of 
metastases was only 4.2 y. 
These figures made us begin to suspect that the 
duration of follow-up was an additional cause for the 
higher than reported 10% incidence of malignant 
pheochromocytoma (in addition to the fact that the 
majority of the patients referred to us were for known 
metastases). Our referral pattern gave “instanta- 
neous” longer follow-up. In addition, Freier (1973, 
1980) and Thompson (1986) had given us a heritage 
of carefully followed patients. Most importantly, we 
began to discover that metastases were detected in 
some of our own patients on whom metastases had 
not been detected during the first year of study. 
[13’I]MIBG occasionally detected metastases not de- 
tected by all other diagnostic or localizing modalities. 
The following are brief summaries of four of these 
patients. 
The first patient illustrates a positive [‘3’I]MIBG 
scan with normal catecholamines. This patient 
also demonstrates the Armed Forces Fasicle No. 9 
statement that in effect all adrenergic tissue is 
embryologically paragangliomas, including the 
normal adrenals (Glenner and Grimly, 1973). 
The second patient showed normalization of cat- 
echolamines during [‘“IIMIBG treatment for malig- 
nant pheochromocytoma metastases but [“‘I]MIBG 
imaging remains positive. 
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Fig. 3. Cumulative incidence of detection of metastases (n = 81) in percent of patients with malignant 
pheochromocytomas, on the ordinate and time in years after histopathological diagnosis of pheo- 
chromocytoma on the abscissa. 
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Fig. 1. Posterior view of MIBG scintiphoto of the chest, showing sharp localization of a pheo- 
chromocytoma in the region of the upper part of the heart in the mediastinum of a 20 year old woman. 
Fig. 2. Posterior abdominal MIBG image localizing two areas of uptake between the kidneys (imaged with 
DTPA and superimposed on the MIBG scintigram in a patient who had recurrent symptoms of 
pheochromocytoma after an apparent “cure” by removal of a pheochromocytoma. Upon operation, the 
tissue near the left kidney was a pheochromocytoma 4 mm in diameter and the pheochromocytoma near 
the right kidney was 2cm in diameter. 
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Fig. 4. Shows a single photon tomography scintiphoto with MIBG of a malignant pheochromocytomh. 
Uptake of MIBG shows that much of the mass does not concentrate MIBG, probably due to necrosis 
(but possibly also to heterogenity of uptake). 
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The third patient showed development of met- 
astases during our follow-up, more bone metastases 
than could be detected by bone scan or CAT scan, 
and pain as the presenting symptom after three 
months of normal plasma urinary catecholamines 
and 1.25 years after a normal [13’I]MIBG image. 
The fourth patient showed metastases detected 
coincidental to a work-up for an interrcurrent illness. 
Because of the findings illustrated by these 
patients, we have begun to obtain yearly [‘3’I]MIBG 
scans on all patients after primary surgery for 
removal of a benign pheochromocytoma. 
[1311]MIBG Treatment of Adrenal Malignant 
Pheochromocytomas 
The hypotheses and goals in using [‘3’I]MIBG for 
the treatment of unresected pheochromocytomas 
(Sisson et al., 1983, 1984) were based on the fact that 
this treatment would result in less symptoms, lower 
blood pressure, reduced catecholamine secretion, and 
smaller tumors without significant toxicity to the 
bone marrow and the autonomic nervous system. 
The criteria used to select patients for this treatment 
were based on tracer dose studies that further indi- 
cated that tumors would receive greater than 
2000 cGy/3.7 GBq (2000 rad/lOO mCi conjugate view 
daily quantitation of radioactivity in tumor, two 
dimensional CAT scans quantitation of volume of 
tumors) doses. Lastly, the criteria for selection in- 
cluded that the tumors were not likely to be lethal to 
the patients in one year, in order to give them time to 
benefit from the therapy dose so that they can return 
for second, third or fourth treatments if necessary. 
responders all received under 13,000 cGy cumulative 
dosage. We were handicapped in the first two patients 
because we did not want to give over 5 mg of 
[‘3’I]MIBG, and thus the patients received under 
3.7 GBq (lOOmCi), in each of the first two doses. 
Fortunately, the first patient showed 55% of his 
administered dose in the abdominal tumor at 24 h 
and the 13’1 had a biologic half life of 4.8 days with 
tllZeff at 3.0 days for a dose of 8000 cGy for 3.6 GBq 
(97 mCi). At this time the volume of his abdominal 
tumor was 327 cm’. After the fourth dose the size of 
the tumor had decreased to 140cm3. It is of im- 
portance that the biologic half-life decreased after 
each dose from 4.8 to 2.7 to 2.0 to 1.6 days, re- 
spectively. As a result, his rad dose progressively 
decreased. Nevertheless, he received a total dose of 
19,790 cGy. This decreasing half-life and uptake of 
each successive dose is also true in the treatment 
of well-differentiated thyroid cancer with sodium 
1311 
Our conclusions were that [‘3’I]MIBG will produce 
clinical and laboratory benefits in some patients with 
malignant pheochromocytomas. Untoward responses 
have been absent or modest. Predictors of success 
were uncertain but high rad dose was necessary. 
[‘3’IIMIBG Treatment of Neuroblastomas 
Present methods of staging neuroblastoma are 
imperfect. Failure to respond to “appropriate” ther- 
apy may be due to errors of staging. [‘3’I]MIBG is a 
more sensitive method of staging than all modalities 
in some cases (Geatti et al., 1985). 
The results of our treatment of the first five patients We have found that [‘3’I]MIBG has been more 
with malignant pheochromocytomas were particu- sensitive than all imaging modalities in differentiating 
larly interesting because the first two patients enjoyed stage I and II. Three out of the first eleven patients 
objective responses while the next three had no treated for neuroblastoma have had an objective 
objective response. The responders were both over 60 remission as shown by pre- and post-treatment CAT 
years of age and the nonresponders were all under 34 scans. These three responders had the slowest growth 
years of age. The metastases in the two responders of the tumor of any of the first 11 patients who were 
were in soft tissues and the metastases in the non- treated. They also received the largest doses (approxi- 
responders were in bone. The responders demon- mately 200 mCi (7.4 GBq)) given three times to each 
strated growth of their metastases in the preceding patient. We are now making arrangements to give 
year, with the first patient showing almost a doubling [‘3’I]MIBG as the first treatment in the patients found 
of tumor size during the previous year. The non- by serum studies to have a poor prognosis. Patients 
responders showed no growth in the first two and with a good prognosis will have [‘311]MIBG adminis- 
doubtful growth in the third patient. The responders tered if they fail to respond to conventional methods 
both received over 15,000 cGy and the non- of treatment. 
Table I. “‘I Distribution in tumors 
[“‘IIMIBG in” [“‘I]Fabb 
malignant fragments in 
pheochromocytoma malignant melanoma 
Percent dose/g 0.18 0.04 
Maximum r,,, (days) 4.8 2.0 
Percent dose uptake/tumor 55.0 (solid & cystic) 17.2 (solid parts only) 
Maximum tumor:liver ratio 68O:l 2:l 
Maximum tumor dose in rad/lOOmCi 
“Sisson et al. (1984) J. Nucl. Med. 24. 191. 
bLarson (1983) J. C/in. Inuesf. 72(6), 2101 
8000 1000 
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WIMIBG in Neuroendocrine Tumors other dose and was the only patient whose urine showed 5 
I 1 
than Pheochromocytomas and Neuroblastomas hydroxylated [1311]MIBG. We are therefore searching 
Shapiro et al. (1986) reported that good imaging 
for metabolic differences between those that might 
of carcinoids in the first four of ten patients, three 
be good responders and those that might be poor 
of three non-secreting paragangliomas, one of five 
responders. 
sporadic medullary thyroid cancers, and one of 
Devita (1983) emphasized that cancer chemo- 
25 familial medullary thyroid cancers. 
therapy is at its best in the treatment of rapidly 
Recently, the uptake of [1311]MIBG in two of five 
growing cancers. Unfortunately, slow growing can- 
chemodectomas, none of four oat cell carcinomas, 
cers account for most cancer deaths. These slow 
one of one choriocarcinomas, one of one atypical 
growing cancers are carcinoma of bowel, the lung, 
schwannoma, one of one Merkel cell skin cancer, and 
prostate and breast. Radiopharmaceutical treatment 
none of one eye lid cell carcinoma has been demon- 
of cancer, on the other hand, is at its best in the slow 
strated by scintigraphy. We have a diagnostic and 
growing cancers. For example, sodium [“‘Iliodide for 
therapeutic IND for the continued diagnosis and 
treating metastatic thyroid cancer and [‘311]MIBG for 
therapy of apudoma patients. 
treating metastatic carcinoma of the adrenal medulla, 
neuroblastomas and possibly for apudomas have 
Comparison sf possible therapeutic parameters with been shown to be effective therapeutic agents. 
t3tI labeled monoclonal antibodies 
Table 1 shows that the usual parameters for 
evaluating the possible therapeutic benefit from 
[13’I]MIBG are strikingly better (Sisson et al., 1984) 
than when these parameters are applied to the treat- 
ment of malignant melanomas with a radioiodinated 
monoclonal antibody fragment to the P-97 antigen 
in malignant melanomas. The percent dose of 
[“‘IIMIBG per gram localizing the tumor is an order 
of magnitude greater than with the [‘311]P-97-MOAb. 
The biological half-life is twice as long, the percent 
dose uptake per tumor mass is more than twice as 
great, and the maximum tumor to liver ratio is orders 
of magnitude higher with [*3’I]MIBG than with the 
MOAb. As a result, the maximum tumor dose in 
cGy (rad)/lOOmCi (3.7 GBq) is 8000cGy from 
[‘3’I]MIBG compared to 1OOOcGy with the mono- 
clonal antibody. 
The Future of [‘311]MIBG 
We are now using single photon tomography to 
refine the calculation of the absorbed rad dose to 
actively metabolizing cells. Figure 4 shows a single 
photon tomography image with [“‘I]MIBG of a 
patient with malignant pheochromocytoma. If this 
image demonstrates the abdominal mass in patient 1 
and if these images show that only l/10 of the 
abdominal tumor was actively concentrating and 
metabolizing the [1311]MIBG, the dose to the tumor in 
this patient is calculated to be 19,790 cGy, assuming 
uniform distribution of the [‘3’I]MIBG throughout 
the tumor. If the single photon tomography with 
[13’I]MIBG had shown that 10% of the total tumor 
was actively metabolizing cancer cells, then the total 
of the absorbed dose might be 10 x 19,790 cGy or 
197,900 cGy. 
A second potential application for ]‘3fI]MIBG is 
demonstrated by a second patient that was treated for 
malignant pheochromocytoma who showed marked 
regression of liver metastases. This patient was the 
only patient with this disease exhibiting an increase in 
uptake of [‘3’I]MIBG with each successive therapy 
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